Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-10-26
2009-11-24
Stucker, Jeffrey (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C514S002600, C514S825000, C530S351000, C530S387100, C530S389200
Reexamination Certificate
active
07622110
ABSTRACT:
The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.
REFERENCES:
patent: 5350683 (1994-09-01), Sims et al.
patent: 5747072 (1998-05-01), Davidson et al.
patent: 5780513 (1998-07-01), McDaniel et al.
patent: 5922573 (1999-07-01), Boraschi et al.
patent: 6096728 (2000-08-01), Collins et al.
patent: 6121266 (2000-09-01), Dolle et al.
patent: 6159460 (2000-12-01), Thompson et al.
patent: 6197551 (2001-03-01), Busfield
patent: 6204261 (2001-03-01), Batchelor et al.
patent: 6268142 (2001-07-01), Duff et al.
patent: 6413511 (2002-07-01), Gloriosos et al.
patent: 6573366 (2003-06-01), Zanette et al.
patent: 6599873 (2003-07-01), Sommer et al.
patent: 6710084 (2004-03-01), Serhan
patent: 7037492 (2006-05-01), Glorioso et al.
patent: 7067144 (2006-06-01), Demopulos et al.
patent: 7192917 (2007-03-01), Tracey et al.
patent: 7446175 (2008-11-01), Gram et al.
patent: 2001/0053764 (2001-12-01), Sims et al.
patent: 2003/0235890 (2003-12-01), Wyllie et al.
patent: 0 547 699 (1993-06-01), None
patent: 93/16710 (1993-09-01), None
De Benedetti, F., et al., 1991, “Correlation of Serum Interleukin-6 Levels with Joint Involvement and Thrombocytosis in Systemic Juvenile Rhematoid Arthritis,” Arthritis Rheum 34:1158-1163.
De Benedetti, F., et al., 1992. “Serum Interleukin-6 Levels and Joint Involvement in Polyarticular and Pauciarticular Juvenile Chronic Arthritis,” Clin Exp Rheumatol 10:493-498.
De Benedetti, F., et al., 1995. “Circulating levels of interleukin 1β and of interleukin 1 receptor antagonist in systemic juvenile chronic arthritis,” Clin Exp Rheumatol 13:779-84.
Frankel, A.E., et al. 2001. “Novel Therapeutics for Chemotherapy-Resistant Acute Myeloid Leukaemia,” BioDrugs 15:55-57.
Hull, K.M., et al., 2003, “The Expanding Spectrum of Systemic Autoinflammatory disorders and Their Rheumatic Manifestations,” Curr Opin Rheumatol 15:61-69.
Ideo, G. and Bellobuono, A., 2002. “New Therapies for the Treatment of Chronic Hepatitis C,” Curr Pharm Des 8:959-966.
Kaplanski, G., et al.1994. “Interleukin-1 Induces Interleukin-8 Secretion from Endothelial Cells by a Juxtacrine Mechanism,” Blood 84:4242-4248.
Kwon, et al., 2004, “Suppressive Effects of Natural and Synthetic Agents on Dexatran Sulfate Sodium-induced Interleukin-1 β from Murine Peritoneal Macrophages,” Biosci. Biotechnol. Biochem. 68 (2):436-437.
Lorenz, H.M. and Kalden J.R., 2001. “Neue Therapieentwicklungen in der Rheumatoiden Arthritis,” Z Rheumatol 60:326-32.
Mangge, H, et al., “Long-Term Follow-Up of Cytokines and Soluble Cytokine Receptors in Peripheral Blood of Patients with Juvenile Rheumatoid Arthritis,” 1999. J Interferon Cytokine Res 19:1005-1010.
Mehta, R.C., et al. 2000. “Intercellular Adhesion Molecule-1 Suppression in Skin by Topical Delivery of Anti-Sense Oligonucleotides,” J Invest Dermatol 115):805-812.
Muller, K, et al. “Inflammatory Cytokines and Cytokine Antagonists in Whole Blood Cultres of Patients with Systemic Juvenile Chronic Arthritis,” 1998. Br J Rheumatol 37:562-569.
Muzaffer, M., et al., 2002, “Differences in the Profiles of Circulating Levels of Soluble Tumor Necrosis Factor Receptors and Interleukin 1 Receptor Antagonist Reflect the Heterogeneity of the Subgroups of Juvenile Rheumatoid Arthritis,” J Rheumatol 29:1071-1078.
Ozen, S, et al. 1997, “Interleukin-1, -6, and -8 Levels in Juvenile Chronic Arthritis,” Clin Rheumatol 16:173-178.
Sandborn, W.J. and Targan, S.R., 2002. “Biologic Therapy of Inflammatory Bowel Disease,” Gastroenterology 122:1592-1608.
Serhan, C.N. and Clish, C.B., 2002, “Aspirin Triggered Lipid Mediators: Novel inhibitors of Leucocyte Trafficking,” Thorax, 55:S10-S12.
Shahin, A., et al., “Circulating interleukin-6, soluble interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-10 levels in juvenile chronic arthritis: correlations with soft tissue vascularity assessed by power Doppler sonography,” 2002. Rheumatol Int 22:84-88.
Yokata, S. 2003. “Interleukin 6 as a herapeutic target in systemic-onset juvenile idiopathic arthritis,” Curr Opin Rheumatol 15:581-586.
Nuki, G., et al., “Long-Term Safety and Maintenance of Clinical Improvement Following Treatment with Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Patients with Rheumatoid Arthritis,” Arthritis and Rheumatism (2002), 46:2838-2846.
Banchereau Jacques F.
Pascual Maria Virginia
Baylor Research Institute
Chalker Flores LLP
Flores Edwin S.
Gucker Stephen
Singleton Chainey P.
LandOfFree
Compositions and methods for the systemic treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the systemic treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the systemic treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4110592